NCT06573008

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 328 (estimated)
• Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.

Conditions

• Influenza, Human

Interventions

Type	Name	Description
DRUG	GP681 40mg	2 x 20mg tablets taken orally
DRUG	GP681 Simulant	Placebo tablets matching GP681 40mg

Timeline

• Start date: 2024-11-11
• Primary completion: 2025-12-30
• Completion: 2025-12-30
• First posted: 2024-08-27
• Last updated: 2024-12-04

Locations

1 site across 1 country: China